Trials / Completed
CompletedNCT01600079
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,505,647 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZOSTAVAX™ | ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use |
Timeline
- Start date
- 2012-05-15
- Primary completion
- 2020-10-16
- Completion
- 2020-10-16
- First posted
- 2012-05-16
- Last updated
- 2022-07-14
Source: ClinicalTrials.gov record NCT01600079. Inclusion in this directory is not an endorsement.